Migraine with Brainstem Aura Clinical Trials

Find Migraine with Brainstem Aura Clinical Trials Near You

A Prospective, Open-Label Study Evaluating the Effectiveness of Rimegepant ODT or Zavegepant Nasal Spray for Acute Treatment of Migraine in the Emergency Department

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

Prospective, single-site, open-label, non-controlled pilot study consisting of two parallel trials. Participants will receive rimegepant or zavegepant for acute migraine treatment during a single Emergency Department visit, with post-discharge follow-up through 28 days. Participants will be allocated to either the rimegepant trial or the zavegepant trial. The study design does not include a placebo or active comparator control group, and the two gepant study drugs are not designed to function as active comparator groups. The objective in this investigation is to examine relief from either rimegepant or zavegepant in separate parallel trials.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• • At least 18 years of age

‣ Capacity to provide informed consent (without a Representative)

⁃ Emergency Department presentation for a headache consistent with migraine, based either on the treating clinical team's judgement, or fulfillment of International Classification of Headache Disorders (ICHD-3) criteria for migraine without aura or with typical aura, or for probable migraine without aura or with typical aura. It is acceptable if current headache duration is \>72 hours. Must have been headache free for \>48 hours prior to current attack.

⁃ Willing to participate in post-discharge telephone assessments

⁃ English and/or Spanish speaking patients

Locations
United States
Florida
Tampa General Hospital Emergency Room
RECRUITING
Tampa
Time Frame
Start Date: 2026-09-15
Estimated Completion Date: 2027-08
Participants
Target number of participants: 100
Treatments
Experimental: Rimegepant (Parallel Trial)
Participants receive a single oral dose of rimegepant 75 mg orally disintegrating tablet during an Emergency Department visit for the acute treatment of migraine.~This arm represents one of two independent, parallel pilot trials evaluating the effectiveness and safety of gepant medications in the Emergency Department. This arm is not intended for comparison with the zavegepant arm.
Experimental: Zavegepant (Parallel Trial)
Participants receive a single dose of zavegepant 10 mg administered as an intranasal spray during an Emergency Department visit for the acute treatment of migraine.~This arm represents one of two independent, parallel pilot trials evaluating the effectiveness and safety of gepant medications in the Emergency Department. This arm is not intended for comparison with the rimegepant arm.
Sponsors
Leads: University of South Florida
Collaborators: Pfizer, Tampa General Hospital

This content was sourced from clinicaltrials.gov